We have previously shown that inhibition of COX-2 activity can reduce the growth of subcutaneous neuroblastoma and medulloblastoma PDXs24, 44, and the enhanced expression of COX-2 in patients with Group 3 medulloblastoma suggest that therapeutic intervention may be particularly useful for this patient group. This evidence concerns the gene PTGS2 and neuroblastoma.